Slu-pp-332
Review specification, purity, and peptide sourcing details for Slu-pp-332. Continue to the inquiry route if you need pricing, lead time, shipping support, or supporting documents for this peptide product.
Product Description
SLU-PP-332: The Novel, Brain-Permeable LXRβ-Selective Agonist for Neurodegeneration Research 🧠🔬
Target CNS Lipid Metabolism with Unprecedented Precision. SLU-PP-332 is not a conventional peptide; it is a first-in-class, synthetic, brain-penetrant agonist exhibiting high selectivity for the Liver X Receptor beta (LXRβ) subtype over LXRα. This pharmacological profile makes it a groundbreaking research tool specifically designed to explore the role of LXRβ in the central nervous system—particularly in clearing toxic protein aggregates, modulating neuroinflammation, and enhancing neuronal resilience—with potential relevance to Alzheimer's, Parkinson's, and other proteinopathies.
SLU-PP-332's CNS-focused action allows you to isolate LXRβ's critical functions in the brain:
·Promotion of Apolipoprotein E (ApoE) Expression: Driving the primary lipid carrier involved in amyloid-beta clearance.
·Enhancement of Phagocytosis: Potentially boosting microglial uptake of pathological protein aggregates.
·Regulation of Neuroinflammation: Modulating glial cell responses to mitigate chronic inflammatory damage.
·Support of Neuronal Energy & Survival: Influencing cholesterol transport and glucose metabolism in neurons.
Peptide FAQ & Support
Buyers often use this page to review peptide specification details, confirm whether certificates are available, and start product-specific inquiries.
For document requests or quotation support, continue to the contact page and include your required quantity, target specification, and shipping destination.